STAT - DESCREPTIVE · ò Ô » î ß ï ¼ £ ù ç ô ß ½ ® Ë Õ ® Á ô ç /hqjwk / Ô ß Ý í Á ³ £ x 5 &odvvhv
Ventac Partners ppt2 · 2015. 12. 16. · W v ^ o d l Z } ®Þ X XOÞ X¶ Î M Ó Î 1 á ß ß °...
Transcript of Ventac Partners ppt2 · 2015. 12. 16. · W v ^ o d l Z } ®Þ X XOÞ X¶ Î M Ó Î 1 á ß ß °...
Driving Innovation And Strategic Excellence in the Life Sciences
www.ventac-partners.com
Why Ventac For Your Life Science Company?
2
• Real-World Operational Experience• Corporate Strategies• New Business Models
• Market & IP Research• Competitive & Pipeline Analysis• Start-ups, spin-outs and early stage
• Due Diligence• Business Development• Product Development Planning
We Bring Real-World, Current Experience To Address Your Analytical And Operational NeedsWe Bring Real-World, Current Experience To Address Your Analytical And Operational Needs
2
Real-World Experience
We Start And Operate New Life Science Companies
Innovation
Venture Capital
Management
• Ventac Partners identifies early-stage assets and technologies from academic and corporate sources• Hundreds of opportunities are reviewed before settling on the best ones with the greatest chance of success
• Ventac Partners creates a new company which licenses the technology• Ventac Partners prepares the business plan and obtains seed funding from investors
• Ventac Partners creates a 2-4 person management team who work for company for equity and low monthly fees• Efficient model means investment is focused on product development, not salaries nor expensive labs/offices
We Start And Build Companies Via A Cost-effective Operational ModelWe Start And Build Companies Via A Cost-effective Operational Model
4
Practicing What We Preach
• We perform market opportunity assessments for our own portfolio opportunities and build data-rich business cases.
• We run out-licensing and fund-raising processes for our portfolio companies…we know what investors and partners are seeking.
• We manage our own companies, so our management and turn-around experiences are real, current, and effective.
Our Advice Is Legitimate Because We Start And Operate Our Own CompaniesOur Advice Is Legitimate Because We Start And Operate Our Own Companies
5
Market Research
Market Research: Foundation For Everything We DoWe Deploy GlobalData And Other Tools For Market ResearchWe Deploy GlobalData And Other Tools For Market Research
7
• Competitive Intelligence Analysis• Disease area strategy and treatment dynamics• Market Assessment• Pipeline landscape analysis• Epidemiology assessments• KOL interviews• Product SWOT and Opportunity Analysis
Always Focused on Value Creation
8
• Commercial Validation• We evaluate commercial opportunities for early-stage assets• Primary and secondary research to build business case• Supported by industry and investment community feedback
• Business Creation• We build the business plan, fundraise and execute, focusing on value creation• We facilitate new company formation, partnering and out-licensing to industry• Our direct experience makes this possible
• Training• We can provide training for management and entrepreneurs• Commercialization, licensing, valuation, patent strategies and company formation• Based on real-world, current information and experiences
8
We Leverage Our Experiences To Develop The Business StrategyWe Leverage Our Experiences To Develop The Business Strategy
Business Development & Related Services
We Serve Investors And Their Companies
• We can provide independent, second opinions on valuations, product and market opportunities, and competitive intelligence
• We run out-licensing and fund-raising processes for our portfolio companies…we know what investors and partners are seeking.
• We can advise portfolio companies on product development plans, from Preclinical through Phase IV.
We Work With Investors And Portfolio Companies On A Daily BasisWe Work With Investors And Portfolio Companies On A Daily Basis
10
We Understand The Need To Drive Towards Exits• Founded 2003• Partnerships with Enzon, GSK, Wyeth, Shire• Acquired for $250 million upfront and an additional contingent payments of $200 million• Danish operations to be renamed Roche Innovation Center Copenhagen
The Recent Acquisition Of Santaris By Roche Provided An Attractive Exit For Ventac And InvestorsThe Recent Acquisition Of Santaris By Roche Provided An Attractive Exit For Ventac And Investors
11
Partners Selected Track RecordFinancing * M&A *
$200,000,000
Strategic Alliance & License
2006
Licensing *
$900,000,000 $380,000,000
2009
$11,500,000
2013
$58,500,000
2010
$500,000,000
2011$917,000,000
2013
$50,000,000
2006
$450,000,000
Acquisition by
2014
$7,500,000
Merged with
2003
*Including transaction completed by partners before joining Ventac Partners
$21,800,000
2013
$348,000,000
2013$1,800,000,000
2013
Strategic Alliance & License
Strategic Alliance & License
Strategic Alliance & License
Strategic Alliance & License
Strategic Alliance & License
Strategic Alliance & LicenseStrategic Alliance & License
Strategic Alliance & License Strategic Alliance & License
Strategic Alliance & License
Series B
2007
2008
$30,000,000
2007$14,000,000
2012
F-1 Prepared
2014
Series C
Preparation for IPO at NASDAQDual Track / M&A by RocheSeries D
$Not disclosed
2007
Co-ownership & LicenseProfessor Imanishi &
Pantheco
$Not disclosed
Acquisition of 8 drugs
2013
$6,700,000
2012
Strategic Alliance & License
$10,000,000
2000
Private Placement to a consortium of Nordic InvestorsLead Manager
$13,000,000
2001
Private Placement to a consortium of Nordic InvestorsSole Manager
$Not disclosed
2000
Worldwide rights to LNA technology
$180,000,000
2000
Worldwide semi-exlusive manufacturing rights to LNA technology
$Not disclosed
2000
Use of LNA in clinical diagnostics
$23,000,000
2004
$10,500,000
2006
$17,000,000
2003
Series BPrivate Financing
Series CPrivate FinancingPrivate Financing
$400,000,000
2005
Strategic Alliance &License
$4,000,000
2014
Series A
$10,300,000
2006
Series A (2nd closing)
$47,000,000
2009
Series B
$35,000,000.
2000
Novartis Research FoundationPartnership
$Not disclosed
Merged with
2014
$Not disclosed
Acquisition of
2014
$700,000,000
2007
$Not disclosed
2009-2015
$10,000,000
2010-2014
$Not disclosed
2004
$Not disclosed
2008
Raises Seed Funds&Series A & B financingStrategic Alliance &License Strategic Alliance &License
Raises Seed Funds&Series A, B & C financing
$2,100,000
2015
Listing on SwedishStock Exchange
$Not disclosed
2011
$Not disclosed
Strategc Alliance &License
2011
Miacom Diagnostics
We’ve done it before…We’ve done it before…
Our Team
21 Partners and 14 offices on 3 Continents
Lund CopenhagenBaselMadrid
Hong Kong
Boulder Boston MunichHelsinki
ViennaDüsseldorf
ShanghaiNew York
We Work Where You Do – And Provide Global ReachWe Work Where You Do – And Provide Global Reach
19
San Francisco(2016)
London
15
Our International Team
Driving Innovation And Strategic Excellence in the Life Sciences
www.ventac-partners.com